Hormonal
Discontinuation of incretin-based pharmacotherapy (GLP-1 or dual GLP-1/GIP agonists) leads to partial or complete weight regain due to the reactivation of homeostatic neurohormonal systems (increased ghrelin, decreased leptin and peptide YY), confirming obesity as a chronic condition requiring long-term management.
If you stop taking your incretin medication (like semaglutide or tirzepatide), your body's natural hunger signals will likely return, causing you to regain the weight you lost. This is a biological response, not a lack of willpower. To keep the weight off, you must treat obesity as a chronic condition and continue your medication and lifestyle habits long-term, just as you would for high blood pressure.
Evidence shows that cessation of GLP-1 receptor agonist therapy leads to partial or complete weight regain, underscoring the need for continued treatment and comprehensive management... Mechanistically, discontinuation leads to reactivation of homeostatic neurohormonal systems that favor weight regain—such as increased ghrelin and decreased leptin and peptide YY levels—highlighting the physiological drive to restore energy balance.
Why this rating
Supported by pivotal phase 3 randomized controlled trials (STEP 4, SURMOUNT-4) with robust long-term follow-up data.
Source
INCRETIN-BASED THERAPIES FOR OBESITY MANAGEMENT: THE IMPACT OF PATIENT EDUCATION AND LIFESTYLE MODIFICATION ON LONG-TERM TREATMENT OUTCOMES
Natalia Senatorska et al. · International Journal of Innovative Technologies in Social Science · 2025
DOI 10.31435/ijitss.4(48).2025.4225
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →